Antimicrobial resistance in community and nosocomial Escherichia coli urinary tract isolates, London 2005-2006

被引：83

作者：

Bean D.C. ^{[1
]}

Krahe D. ^{[2
]}

Wareham D.W. ^{[1
,2
,3
]}

机构：

[1] Centre for Infectious Disease, Institute of Cell and Molecular Science, Barts and The London, Queen Mary's School of Medicine and Dentistry, London

[2] Department of Medical Microbiology, Homerton University Foundation NHS trust, London

[3] Division of Infection, Barts and The London NHS Trust, London

来源：

Annals of Clinical Microbiology and Antimicrobials | / 7卷 / 1期

关键词：

Urinary Tract Infection; Trimethoprim; Nitrofurantoin; Fosfomycin; Cefpodoxime;

D O I：

10.1186/1476-0711-7-13

中图分类号：

学科分类号：

摘要：

Background: Escherichia coli is the commonest cause of community and nosocomial urinary tract infection (UTI). Antibiotic treatment is usually empirical relying on susceptibility data from local surveillance studies. We therefore set out to determine levels of resistance to 8 commonly used antimicrobial agents amongst all urinary isolates obtained over a 12 month period. Methods: Antimicrobial susceptibility to ampicillin, amoxicillin/ clavulanate, cefalexin, ciprofloxacin, gentamicin, nitrofurantoin, trimethoprim and cefpodoxime was determined for 11,865 E. coli urinary isolates obtained from community and hospitalised patients in East London. Results: Nitrofurantoin was the most active agent (94% susceptible), followed by gentamicin and cefpodoxime. High rates of resistance to ampicillin (55%) and trimethoprim (40%), often in combination were observed in both sets of isolates. Although isolates exhibiting resistance to multiple drug classes were rare, resistance to cefpodoxime, indicative of Extended spectrum β-lactamase production, was observed in 5.7% of community and 21.6% of nosocomial isolates. Conclusion: With the exception of nitrofurantoin, resistance to agents commonly used as empirical oral treatments for UTI was extremely high. Levels of resistance to trimethoprim and ampicillin render them unsuitable for empirical use. Continued surveillance and investigation of other oral agents for treatment of UTI in the community is required. © 2008 Bean et al; licensee BioMed Central Ltd.

引用

共 15 条

[1]

Baerheim A., Empirical treatment of uncomplicated cystitis, BMJ, 323, pp. 1197-1198, (2001)

[2]

Gupta K., Hooton T.M., Stamm W.E., Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections, Ann Intern Med, 135, pp. 41-50, (2001)

[3]

Farrell D.J., Morrissey I., De Rubeis D., Robbins M., Felmingham D., A UK multicentre study of the antimicrobial susceptibility of bacterial pathogens causing urinary tract infection, J Infect, 46, pp. 94-100, (2003)

[4]

Bean D.C., Livermore D.M., Papa I., Hall L.M., Resistance among Escherichia coli to sulphonamides and other antimicrobials now little used in man, J Antimicrob Chemother, 56, pp. 962-964, (2005)

[5]

Potz N.A., Hope R., Warner M., Johnson A.P., Livermore D.M., Prevalence and mechanisms of cephalosporin resistance in Enterobacteriaciae in London and South East England, J Antimicrob Chemother, 58, pp. 320-326, (2006)

[6]

Lipsky B.A., Urinary tract infections in men, Epidemiology, Pathophysiology, Diagnosis, and Treatment, 110, pp. 138-150, (1989)

[7]

Shannon K.P., French G.L., Increasing resistance to antimicrobial agents of Gram-negative organisms isolated at a London teaching hospital, 1995 - 2000, J Antimicrob Chemother, 53, pp. 818-825, (2004)

[8]

Hope R., Potz N.A., Warner M., Fagan E.J., Arnold E., Livermore D.M., Efficacy of practised screening methods for detection of cephalosporin-resistant Enterobacteriaceae, J Antimicrob Chemother, 59, pp. 110-113, (2007)

[9]

Livermore D.M., Canton R., Gniadkowski M., Nordmann P., Rossolini G.M., Arlet G., Ayala J., Coque T.M., Kern-Zadanowicz I., Luzzaro F., Poirel L., Woodford N., CTX-M: Changing the face of ESBLs in Europe, J Antimicrob Chemother, 59, pp. 165-174, (2007)

[10]

Karisk E., Ellington M.J., LIvermore D.M., Woodford N., Virulence factors in Escherichia coli with CTX-M-15 and other extended spectrum β-lactamases in the UK, J Antimicrob Chemother, 61, pp. 54-58, (2008)

← 1 2 →